Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract
Autor(a) principal: | |
---|---|
Data de Publicação: | 2024 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Biology |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1519-69842024000100288 |
Resumo: | Abstract The gastrointestinal microflora regulates the body’s functions and plays an important role in its health. Dysbiosis leads to a number of chronic diseases such as diabetes, obesity, inflammation, atherosclerosis, etc. However, these diseases can be prevented by using probiotics – living microorganisms that benefit the microflora and, therefore, improve the host organism's health. The most common probiotics include lactic acid bacteria of the Bifidobacterium and Propionibacterium genera. We studied the probiotic properties of the following strains: Bifidobacterium adolescentis АС-1909, Bifidobacterium longum infantis АС-1912, Propionibacterium jensenii В-6085, Propionibacterium freudenreichii В-11921, Propionibacterium thoenii В-6082, and Propionibacterium acidipropionici В-5723. Antimicrobial activity was determined by the ‘agar blocks’ method against the following test cultures: Escherichia coli ATCC 25922, Salmonella enterica ATCC 14028, Staphylococcus aureus ATCC 25923, Pseudomonas aeruginosa B6643, Proteus vulgaris ATCC 63, and Listeria monocytogenes ATCC 7644. Moderate antimicrobial activity against all the test cultures was registered in Bifidobacterium adolescentis АС-1909, Propionibacterium jensenii В-6085, and Propionibacterium thoenii В-6082. Antioxidant activity was determined by the DPPH inhibition method in all the lactic acid strains. Our study indicated that some Propionibacterium and Bifidobacterium strains or, theoretically, their consortia could be used as probiotic cultures in dietary supplements or functional foods to prevent a number of chronic diseases. |
id |
IIE-1_b86bac3a2d5c8b2f6624c5fcf8805f1c |
---|---|
oai_identifier_str |
oai:scielo:S1519-69842024000100288 |
network_acronym_str |
IIE-1 |
network_name_str |
Brazilian Journal of Biology |
repository_id_str |
|
spelling |
Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tractlactic acid bacteriabifidobacteriapropionic acid bacteriabiocompatibilityAbstract The gastrointestinal microflora regulates the body’s functions and plays an important role in its health. Dysbiosis leads to a number of chronic diseases such as diabetes, obesity, inflammation, atherosclerosis, etc. However, these diseases can be prevented by using probiotics – living microorganisms that benefit the microflora and, therefore, improve the host organism's health. The most common probiotics include lactic acid bacteria of the Bifidobacterium and Propionibacterium genera. We studied the probiotic properties of the following strains: Bifidobacterium adolescentis АС-1909, Bifidobacterium longum infantis АС-1912, Propionibacterium jensenii В-6085, Propionibacterium freudenreichii В-11921, Propionibacterium thoenii В-6082, and Propionibacterium acidipropionici В-5723. Antimicrobial activity was determined by the ‘agar blocks’ method against the following test cultures: Escherichia coli ATCC 25922, Salmonella enterica ATCC 14028, Staphylococcus aureus ATCC 25923, Pseudomonas aeruginosa B6643, Proteus vulgaris ATCC 63, and Listeria monocytogenes ATCC 7644. Moderate antimicrobial activity against all the test cultures was registered in Bifidobacterium adolescentis АС-1909, Propionibacterium jensenii В-6085, and Propionibacterium thoenii В-6082. Antioxidant activity was determined by the DPPH inhibition method in all the lactic acid strains. Our study indicated that some Propionibacterium and Bifidobacterium strains or, theoretically, their consortia could be used as probiotic cultures in dietary supplements or functional foods to prevent a number of chronic diseases.Instituto Internacional de Ecologia2024-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1519-69842024000100288Brazilian Journal of Biology v.84 2024reponame:Brazilian Journal of Biologyinstname:Instituto Internacional de Ecologia (IIE)instacron:IIE10.1590/1519-6984.256945info:eu-repo/semantics/openAccessDyshlyuk,L. S.Milentyeva,I. S.Asyakina,L. K.Ostroumov,L. A.Osintsev,A. M.Pozdnyakova,A. V.eng2022-05-02T00:00:00Zoai:scielo:S1519-69842024000100288Revistahttps://www.scielo.br/j/bjb/https://old.scielo.br/oai/scielo-oai.phpbjb@bjb.com.br||bjb@bjb.com.br1678-43751519-6984opendoar:2022-05-02T00:00Brazilian Journal of Biology - Instituto Internacional de Ecologia (IIE)false |
dc.title.none.fl_str_mv |
Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract |
title |
Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract |
spellingShingle |
Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract Dyshlyuk,L. S. lactic acid bacteria bifidobacteria propionic acid bacteria biocompatibility |
title_short |
Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract |
title_full |
Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract |
title_fullStr |
Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract |
title_full_unstemmed |
Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract |
title_sort |
Using bifidobacterium and propionibacterium strains in probiotic consortia to normalize the gastrointestinal tract |
author |
Dyshlyuk,L. S. |
author_facet |
Dyshlyuk,L. S. Milentyeva,I. S. Asyakina,L. K. Ostroumov,L. A. Osintsev,A. M. Pozdnyakova,A. V. |
author_role |
author |
author2 |
Milentyeva,I. S. Asyakina,L. K. Ostroumov,L. A. Osintsev,A. M. Pozdnyakova,A. V. |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Dyshlyuk,L. S. Milentyeva,I. S. Asyakina,L. K. Ostroumov,L. A. Osintsev,A. M. Pozdnyakova,A. V. |
dc.subject.por.fl_str_mv |
lactic acid bacteria bifidobacteria propionic acid bacteria biocompatibility |
topic |
lactic acid bacteria bifidobacteria propionic acid bacteria biocompatibility |
description |
Abstract The gastrointestinal microflora regulates the body’s functions and plays an important role in its health. Dysbiosis leads to a number of chronic diseases such as diabetes, obesity, inflammation, atherosclerosis, etc. However, these diseases can be prevented by using probiotics – living microorganisms that benefit the microflora and, therefore, improve the host organism's health. The most common probiotics include lactic acid bacteria of the Bifidobacterium and Propionibacterium genera. We studied the probiotic properties of the following strains: Bifidobacterium adolescentis АС-1909, Bifidobacterium longum infantis АС-1912, Propionibacterium jensenii В-6085, Propionibacterium freudenreichii В-11921, Propionibacterium thoenii В-6082, and Propionibacterium acidipropionici В-5723. Antimicrobial activity was determined by the ‘agar blocks’ method against the following test cultures: Escherichia coli ATCC 25922, Salmonella enterica ATCC 14028, Staphylococcus aureus ATCC 25923, Pseudomonas aeruginosa B6643, Proteus vulgaris ATCC 63, and Listeria monocytogenes ATCC 7644. Moderate antimicrobial activity against all the test cultures was registered in Bifidobacterium adolescentis АС-1909, Propionibacterium jensenii В-6085, and Propionibacterium thoenii В-6082. Antioxidant activity was determined by the DPPH inhibition method in all the lactic acid strains. Our study indicated that some Propionibacterium and Bifidobacterium strains or, theoretically, their consortia could be used as probiotic cultures in dietary supplements or functional foods to prevent a number of chronic diseases. |
publishDate |
2024 |
dc.date.none.fl_str_mv |
2024-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1519-69842024000100288 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1519-69842024000100288 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1519-6984.256945 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Instituto Internacional de Ecologia |
publisher.none.fl_str_mv |
Instituto Internacional de Ecologia |
dc.source.none.fl_str_mv |
Brazilian Journal of Biology v.84 2024 reponame:Brazilian Journal of Biology instname:Instituto Internacional de Ecologia (IIE) instacron:IIE |
instname_str |
Instituto Internacional de Ecologia (IIE) |
instacron_str |
IIE |
institution |
IIE |
reponame_str |
Brazilian Journal of Biology |
collection |
Brazilian Journal of Biology |
repository.name.fl_str_mv |
Brazilian Journal of Biology - Instituto Internacional de Ecologia (IIE) |
repository.mail.fl_str_mv |
bjb@bjb.com.br||bjb@bjb.com.br |
_version_ |
1752129891266985984 |